Business Wire

YARD-FORCE-UK

19.1.2023 06:23:36 CET | Business Wire | Press release

Share
TV Gardener & Chartered Horticulturist, David Domoney Highlights the Best Time to Do Gardening Jobs Using Power Tools

David Domoney highlights the ever-growing garden trend of manicuring. Keeping a neat and tidy garden is important, especially with the rise in popularity of outdoor entertaining. From trimming hedges and edges of lawns to cleaning your patio for a pristine garden, choosing the right tool for the job is crucial. With so much choice in the market, selecting powered garden tools to make the job of garden manicuring both easy, professional and all importantly, fun is a hot topic. In partnering with Yard Force®, David Domoney hopes to encourage people into their gardens and highlight the right time to do specific green preening tasks in the year. Utilising the tools at the right time of the year ensures you get the most out of them as well as making sure your garden is in the best shape.

David said, “By selecting the right tool for the job, it enables you to get the task at hand done most effectively and efficiently, so you have more time to spend enjoying a beautiful garden. In learning when is best to trim hedges, mow the lawn and general garden maintenance, we make time in the garden so much more enjoyable whilst protecting garden wildlife. It opens doors to learning new gardening techniques that will become part of regular gardening routines for a well-cared-for garden.”

Yard Force® is an internationally recognised brand with years of industry experience and knowledge.

David continues, “Giving people access to a better gardening experience is always a good thing; with practical advice on making the most of their garden and the tools necessary to give great results with little effort. The more we can do using professional electric-powered equipment at the right time of year, leaves us more time to enjoy the garden.

I want to make the tasks in the garden both rewarding and fun and using practical power tools that take the hard work out of garden maintenance. The range of cordless products and battery-share technology makes the range hassle-free, convenient, and a more sustainable option for beginners and keen gardeners alike. Within Yard Force’s 40V range, there is the Cordless Lawnmower, Hedge Trimmer, Grass Trimmer which are really innovative products that showcase game-changing technology.”

The partnership between David Domoney and Yard Force continues to encourage budding gardeners and virtuosos to get outside and give their gardens the best care. Through instructive videos, demos, gardening tips and fantastic giveaways, the knowledge and expertise will promote the range and how to get the most from the tools.

Notes to Editors:

David Domoney:

David Domoney is a seasoned gardening television broadcaster and currently presents on ITV’s ‘Love Your Garden’, ‘Love Your Weekend’ and is also the gardening presenter for ITV’s ‘This Morning’. He is a winner of 30 RHS Medals with two Best in Show category trophies and the Prince Edward Award for Horticulture Excellence. David is also known for pioneering campaigns Cultivation Street as well as Illumination Street, brightening up Britain’s streets at Christmas. David also writes a gardening column for Grow Your Own magazine.

www.daviddomoney.com

Yard Force UK:

Yard Force are excited and proud to announce that we have partnered with seasoned gardening television presenter David Domoney to endorse our range of innovative, durable and high-performance garden power tools.

David is best known for presenting ITV’s most popular Gardening Show ‘Love your Garden’ and is also the resident gardening presenter for ITV’s flagship daytime show ‘This Morning’.

David's 40 years’ of experience in horticulture and dynamic enthusiastic character made him the perfect choice to collaborate with to help endorse our innovative and quality lead products.

Introducing a household name to represent our brand instils the confidence we have in our products and their performance. David says:

Like anything in the garden, once you know how, it becomes so easy. In learning how to look after our gardens properly, using power tools where needed, we make time in the garden so much more enjoyable and open doors to learning new gardening techniques and having access to a healthy and well-cared-for garden.”

We will be working closely with David throughout the year to produce top gardening tips for you to use around the garden, create some instructive videos designed to encourage you and your family to get back outside and exciting GIVEAWAYS featuring chosen products. To be in with the chance of winning and accessing these great promotions we have created a dedicated promotional code which will enable you to receive discounts and added extras all year round! All you need to do is:

SIGN UP TO RECEIVE THE PROMOTIONAL CODE below:
www.yardforce.eu/david

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005607/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release

The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye